Finerenone Tablets 20 mg

What is finerenone?

Finerenone is used in adults with chronic kidney disease related to diabetes mellitus type 2, to reduce the risk of:

• • kidney problems getting worse;
  • a heart attack;
  • needing to be hospitalized for heart failure; or
  • death from heart failure.

Finerenone may also be used for purposes not listed in this medication guide.

Before taking this medicine

You should not use finerenone if you are allergic to it, or if you have problems with your adrenal gland.

Some drugs should not be used with finerenone. Your treatment plan may change if you also use:

• • nefazodone;
  • an antibiotic–clarithromycin, telithromycin;
  • antifungal medicine–itraconazole, ketoconazole, posaconazole, voriconazole; or
  • antiviral medicine for HIV or hepatitis C–boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, ombitasvir, paritaprevir saquinavir, telaprevir, tipranavir.

Tell your doctor if you have ever had:

• severe liver disease; or
• high blood levels of potassium (hyperkalemia).

It is not known if finerenone will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

You should not breastfeed while using finerenone, and for at least 1 day after your last dose.

Not approved for use by anyone younger than 18 years old.

How should I take finerenone?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.

You may take finerenone with or without food.

If you cannot swallow a tablet whole, crush the tablet and mix it with water or soft food such as applesauce. Swallow the mixture right away.

You will need medical tests.

Store at room temperature away from moisture and heat.

Finerenone dosing information

Usual Adult Dose for Chronic Kidney Disease:

Initial dose:
-For estimated glomerular filtration rate (eGFR) at least 60 mL/min/1.73 m2: 20 mg orally once a day
-For eGFR 25 to less than 60 mL/min/1.73 m2: 10 mg orally once a day
Target dose: 20 mg orally once a day

Comments:
-Initiation of therapy is not recommended if serum potassium is greater than 5 mEq/L; if serum potassium levels are greater than 4.8 to 5 mEq/L, initiation of therapy may be considered with additional serum potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels.
-Initiation of therapy is not recommended in patients with eGFR less than 25 mL/min/1.73 m2.

Use: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in patients with chronic kidney disease associated with type 2 diabetes